Gilead Sciences, Inc. GILD

Full chart Compare
Set alert

Price alert · GILD

All alert types
171.02 USD -3.46 (-1.98%)

Nov 5, 2026, 1:20 PM EST

169.94 Day range 176.58
118.15 52-week range 174.48
YTD
+39.34%
1 year
+39.52%
Market cap
211.83B
Revenue (ttm)
30.99B
Profit margin
-12.46%
EPS (ttm)
-3.13
Shares out
1.24B
Forward P/E
17.29
Dividend
3.28 (1.93%)
Ex-dividend date
Dec 14, 2026
YTD return
+39.34%
1-year return
+39.52%
Volume
4.77M
Avg volume
6.06M
Open
175.17
Previous close
174.48
Day's range
169.94 – 176.58
52-week range
118.15 – 174.48
Beta
0.37
Analysts
Buy
Price target
172.50 (+0.9%)
Earnings date
Feb 9, 2027

2Y +79.92 (+88.58%)

100150Jan 25Jun 25Nov 25Apr 26Aug 26170.14

Key statistics

Enterprise value
225.91B
PEG ratio
2.48
Price / sales
6.98
Price / book
16.60
Dividend yield
1.96%
Payout ratio
43.46%
Revenue growth
6.80%
Free cash flow
10.68B
Total cash
7.95B
Total debt
26.23B
Return on equity
-22.45%
Short % of float
1.63%
50-day average
151.77
200-day average
140.34

Financials — quick view

All financials
GILD Revenue — quarterly 8.30B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
GILD Net income — quarterly 2.43B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
GILD EPS — quarterly 1.96
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

GILD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 9, 2027Dec 30, 20261.39———
Oct 29, 2026Sep 30, 20262.192.55+0.36+16.44%
Aug 3, 2026Jun 30, 2026-7.25-6.75+0.50+6.90%
May 7, 2026Mar 31, 20261.912.03+0.12+6.28%
Feb 10, 2026Dec 31, 20251.811.86+0.05+2.76%
Oct 30, 2025Sep 30, 20252.132.47+0.34+15.96%

Upgrades / downgrades

GILD analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026UBSmainBuyBuy
Oct 30, 2026JP MorganmainOverweightOverweight
Oct 30, 2026CitigroupmainBuyBuy
Oct 30, 2026ScotiabankmainSector OutperformSector Outperform
Oct 30, 2026TD CowenmainBuyBuy
Oct 30, 2026Morgan StanleymainOverweightOverweight

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
gilead.com

News

Your note

Sign in to keep a note on GILD — it syncs with the Stock Master app.

Insider holders

GILD insider holders
InsiderRelationLatest transactionDateShares held
BARTON JACQUELINE KDirectorStock Award(Grant)Apr 29, 202627,202
BERGER DIETMAR P.OfficerConversion of Exercise of derivative securitySep 9, 202619,522
DICKINSON ANDREW DChief Financial OfficerSaleSep 14, 2026164,096
MANWANI HARISHDirectorStock Award(Grant)Apr 29, 202615,015
MERCIER JOHANNAOfficerSaleSep 14, 2026116,684
O'DAY DANIEL PATRICKChief Executive OfficerSaleNov 1, 2026551,683

Institution ownership

GILD institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.82%121,844,10821.26BJun 29, 2026
Vanguard Capital Management LLC6.54%81,091,73414.15BJun 29, 2026
FMR, LLC5.39%66,870,81611.67BJun 29, 2026
State Street Corporation4.94%61,216,55210.68BJun 29, 2026
Capital World Investors3.30%40,988,9757.15BJun 29, 2026
Invesco Ltd.3.21%39,819,1516.95BJun 29, 2026

Fund ownership

GILD fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%39,416,8936.88BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%32,173,7505.61BJun 29, 2026
Invesco QQQ Trust, Series 12.09%25,899,6724.52BSep 29, 2026
Dodge & Cox Funds-Dodge & Cox Stock Fund1.39%17,282,8123.02BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%16,522,3152.88BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%16,114,4162.81BSep 29, 2026